Stockscreener 앱 받기
10.20
2.20%
0.22
전일 마감가:
$9.98
열려 있는:
$10.06
하루 거래량:
10,631
Relative Volume:
0.05
시가총액:
$637.03M
수익:
-
순이익/손실:
$-41.43M
주가수익비율:
-12.91
EPS:
-0.79
순현금흐름:
$-39.97M
1주 성능:
-5.56%
1개월 성능:
+13.46%
6개월 성능:
+12.21%
1년 성능:
-19.94%
1일 변동 폭
$9.52
$10.28
1주일 범위
$9.4557
$11.22
52주 변동 폭
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
GHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
10.09 | 637.03M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.33 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.54 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.33 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.74 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.78 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2025-03-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-02-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 개시 | H.C. Wainwright | Buy |
| 2022-06-16 | 개시 | ROTH Capital | Buy |
Gh Research Plc 주식(GHRS)의 최신 뉴스
GH Research Showcases Promising Depression Treatment Data at ASCP Meeting - TipRanks
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting - TradingView
GH Research’s (GHRS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Guggenheim Cuts GH Research (NASDAQ:GHRS) Price Target to $29.00 - Defense World
GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus
GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus
GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks
GH Research PLC Reports Positive Phase 2b Trial Results for GH001 in Treatment-Resistant Depression and Financial Update for Q1 2025 - Nasdaq
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance
Where are the Opportunities in (GHRS) - news.stocktradersdaily.com
Hims & Hers Health (NYSE:HIMS) Shares Down 8.3% Following Insider Selling - American Banking and Market News
Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
What Will GH Research PLC (NASDAQ: GHRS) Be Like In 2025 - Stocksregister
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
(GHRS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
(GHRS) Proactive Strategies - news.stocktradersdaily.com
How To Trade (GHRS) - news.stocktradersdaily.com
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance
Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
GH Research PLC (GHRS) Shares Rise Despite Market Challenges - The News Heater
How to Take Advantage of moves in (GHRS) - news.stocktradersdaily.com
GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada - Defense World
GH Research PLC (NASDAQ:GHRS) Receives $30.67 Consensus PT from Brokerages - Defense World
Q1 Earnings Forecast for GH Research Issued By HC Wainwright - Defense World
RBC Capital Initiates Coverage of GH Research (GHRS) with Outperform Recommendation - Nasdaq
FY2029 EPS Estimates for GH Research Lifted by HC Wainwright - Defense World
GH Research initiated with an Outperform at RBC Capital - TipRanks
GH Research PLC Reports 2024 Financial Results and Clinical Progress - TipRanks
H.C. Wainwright maintains $40 target on GH Research stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $40 target on GH Research stock - Investing.com
Postpartum Depression Pipeline Revealed in 2025 Forecast Report Featuring GH Research, Reunion Neuroscience, Lipocine, and Brii Biosciences - GlobeNewswire Inc.
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025 - MSN
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
GH Research (GHRS) to Release Quarterly Earnings on Thursday - MarketBeat
GH Research (NASDAQ:GHRS) Announces Quarterly Earnings Results - MarketBeat
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Psychedelic: GH Research, Compass Pathways report earnings results - Yahoo Finance
GH Research (NASDAQ:GHRS) Given New $32.00 Price Target at Stifel Nicolaus - MarketBeat
GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
Form F-3 GH Research PLC - StreetInsider.com
GH Research Reports 2024 Financial Results and Clinical Progress - TipRanks
Can GH Research's Depression Drug Change Treatment Paradigms? Phase 2b Shows Striking 57.5% Remission Rate - StockTitan
GH Research PLC Provides Business Updates and Financial Results, Advances Clinical Trials for GH001 in Treatment-Resistant Depression - Nasdaq
Stifel raises GH Research stock target to $32 on strong trial data - Investing.com
Stifel raises GH Research stock target to $32 on strong trial data By Investing.com - Investing.com South Africa
Gh Research Plc (GHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
1.03%
자본화:
|
볼륨(24시간):